Samuel Waxman Cancer Research Foundation Appoints Robert Hromas, MD, to Its Scientific Advisory Board


Get Permission

Robert Hromas, MD

Robert Hromas, MD

The Samuel Waxman Cancer Research Foundation (SWCRF) announced the addition of cancer researcher Robert Hromas, MD, Chair of Medicine at University of Florida Health, to its scientific advisory board (SAB). Dr. Hromas, who continues his position at the University of Florida Health, will join his fellow SWCRF SAB members at the Waxman Foundation’s scientific review and symposium on May 1–2 to evaluate progress reports from the foundation’s funded researchers as part of the SWCRF’s annual grant renewal process.

The SWCRF SAB, together with the foundation’s scientific leaders, approves grant proposals submitted by scientists with National Cancer Institute (NCI)-approved research programs. The board includes Steven D. Gore, MD, Director of Hematologic Malignancies at Yale Cancer Center and Clinical Program Leader for Hematology at Smilow Cancer Hospital at Yale-New Haven; ­Lorraine Gudas, PhD, Chair of Pharmacology at Weill Cornell Medical Center; Ramon ­Parsons, MD, PhD, Professor and Chair of Oncological Sciences at the Icahn School of Medicine at Mount Sinai; ­Nancy Speck, PhD, Professor of Cell and Developmental Biology at the University of Pennsylvania; and Hua Yu, PhD, Professor of Cancer Immunotherapeutics and Tumor Immunology at City of Hope.

The SWCRF’s scientific leadership includes Samuel Waxman, MD, Founder and CEO; Jonathan D. Licht, MD, Director of the University of Florida Health Center, Chief Scientific Officer; and Alan G. Rosmarin, MD, Chief of Hematology/Oncology at UMass Memorial Cancer Center of Excellence, Chief Mission Officer.

About Robert Hromas, MD

Dr. Hromas is the Chair of Medicine at University of Florida Health, where he is also Vice President of the University of Florida Physicians Clinical Practice Association and a member of the University of Florida Health Executive Board. His research has been continuously National Institutes of Health (NIH)-funded for over 2 decades, and he has chaired multiple NIH and American Cancer Society study sections. Among his research activities, Dr. Hromas has isolated and characterized multiple hematopoietic transcription factors, chemokines and cytokines, and leukemia translocations; isolated the first functional human transposase and demonstrated that it was critical to DNA replication and repair; and identified a novel component of homologous recombination DNA repair that is the key decision point for DNA repair pathway choice. ■



Advertisement

Advertisement



Advertisement